<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118516</url>
  </required_header>
  <id_info>
    <org_study_id>ASC43F-101</org_study_id>
    <nct_id>NCT05118516</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC43F, a Fixed-dose Combination (FDC) Oral Tablet Containing ASC41, a THR β Agonist and ASC42, an FXR Agonist in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gannex Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gannex Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label study in healthy adults. This study is aimed at evaluating the&#xD;
      safety, tolerability, and pharmacokinetics of ASC43F, a fixed-dose combination (FDC) and&#xD;
      single dose tablet containing ASC41, a THR β agonist and ASC42, an FXR agonist in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ASC43F evaluated by incidence of treatment emergent adverse events (TEAEs).</measure>
    <time_frame>Baseline to day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics as assessed by Cmax (Max Concentration) of ASC43F tablet following a single fixed oral dose in healthy subjects</measure>
    <time_frame>Baseline to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics as assessed by Area Under the Curve (AUC) of ASC43F tablet following a single fixed oral dose in healthy subjects</measure>
    <time_frame>Baseline to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics as assessed by Tmax (Time to Max Concentration) of ASC43F tablet following a single fixed oral dose in healthy subjects</measure>
    <time_frame>Baseline to day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC43F for all subjects under the fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC43F</intervention_name>
    <description>One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 to 65 years of age.&#xD;
&#xD;
          -  Subjects must weigh at least 50 kg (110 pounds [lbs.]) for men, and at least 45 kg (99&#xD;
             lbs.) for women and body mass index (BMI) within the range 18.5-32 kilogram per meter&#xD;
             square (kg/m2).&#xD;
&#xD;
          -  Physical examination and vital signs are within normal range or slightly abnormal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any surgical or medical condition which in the opinion of the investigator, might&#xD;
             significantly alter the absorption, distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          -  Abnormal clinical or laboratory findings that indicate diseases including but not&#xD;
             limited to renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary,&#xD;
             immunologic disease.&#xD;
&#xD;
          -  History or current electrocardiogram (ECG) abnormalities, arrhythmias or heart valve&#xD;
             diseases.&#xD;
&#xD;
          -  History of viral hepatitis or HIV&#xD;
&#xD;
          -  History of drug or food allergies that caused severe hypersensitivity reactions or&#xD;
             anaphylaxis.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gannex Study Doctor</last_name>
    <phone>+86 571 85389730</phone>
    <email>clinicaltrials@ascletis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>8307 Gault Lane</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gannex Study Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 31, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASC43F</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Thyroid hormone receptor beta agonist</keyword>
  <keyword>FXR agonist</keyword>
  <keyword>ASC41</keyword>
  <keyword>ASC42</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

